Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.82 |
| ▸ | MAPT | P10636 | 6/20 | 0.73 |
| ▸ | MEN1 | O00255 | 4/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.73 |
| ▸ | RAB9A | P51151 | 2/20 | 0.73 |
| ▸ | HTT | P42858 | 2/20 | 0.73 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.73 |
| ▸ | VCP | P55072 | 2/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | MBD2 | Q9UBB5 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | CLK1 | P49759 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.64 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.64 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | AGER | Q15109 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4742547 | 0.90 | ALOX5 (1.00) | ALOX5MAPTMEN1KMT2AMAPK1 | |
| SCHEMBL7114964 | 0.86 | ALOX5 (1.00) | ALOX5MAPTMEN1KMT2AMAPK1 | |
| SCHEMBL7115473 | 0.86 | ALOX5 (0.73) | ALOX5MAPTMEN1KMT2AMAPK1 | |
| SCHEMBL996232 | 0.84 | RAB9A (1.00) | ALOX5MAPTMEN1KMT2AMAPK1 | |
| SCHEMBL1885179 | 0.83 | MEN1 (0.77) | ALOX5MAPTMEN1KMT2AMAPK1 | |
| SCHEMBL1881369 | 0.83 | CYP1A1 (0.88) | ALOX5MAPTMEN1KMT2AMAPK1 | |
| SCHEMBL1887057 | 0.83 | MEN1 (0.77) | ALOX5MAPTMEN1KMT2AMAPK1 | |
| SCHEMBL12298058 | 0.83 | ALOX5 (0.64) | ALOX5MAPTMEN1KMT2AMAPK1 | |
| SCHEMBL1882991 | 0.82 | VCP (1.00) | ALOX5MAPTMEN1KMT2AMAPK1 | |
| SCHEMBL4743091 | 0.82 | MEN1 (0.73) | ALOX5MAPTMEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105436-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-05-05 | — | — | US | claimed |
| WO-2009114552-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2009-09-17 | — | — | WO | claimed |
| EP-2411526-A2 | GANGLIOSIDE BIOSYNTHESIS MODULATORS | Zacharon Pharmaceuticals, Inc. (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20110105436-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-05-05 | — | — | US | disclosed |
| US-20110105436-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-05-05 | — | — | US | disclosed |
| US-20110105436-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-05-05 | — | — | US | disclosed |
| US-20100248365-A1 | GANGLIOSIDE BIOSYNTHESIS MODULATORS | ZACHARON PHARMACEUTICALS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100248365-A1 | GANGLIOSIDE BIOSYNTHESIS MODULATORS | ZACHARON PHARMACEUTICALS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| WO-2010111711-A2 | GANGLIOSIDE BIOSYNTHESIS MODULATORS | ZACHARON PHARMACEUTICALS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| WO-2009114552-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009114552-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105436-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | VHL, TP53, BECN1 | ALOX5 2463/4885MAPT 2506/4885MEN1 3092/4885 |
| US-20100248365-A1 | GANGLIOSIDE BIOSYNTHESIS MODULATORS | UGCG, MAGT1, STT3B | ALOX5 1965/4885MAPT 4120/4885MEN1 1262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.